Steven J. Geary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven J. Geary has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
X. Liao
Department of Pathobiology and Veterinary Sciences and the Center of Excellence for Vaccine Research, University of Connecticut, Storrs, Connecticut, USA
8 shared publicationsE. R. Tulman
Department of Pathobiology and Veterinary Science, Center of Excellence for Vaccine Research, University of Connecticut, Storrs, Connecticut, USA
7 shared publicationsS. M. Szczepanek
Department of Pathobiology and Veterinary Science, Center of Excellence for Vaccine Research, University of Connecticut, Storrs, Connecticut, USA
7 shared publications- Arlind B. Mara
The Center of Excellence for Vaccine Research, Department of Pathobiology, University of Connecticut, Storrs, Connecticut, USA
6 shared publications Edan R. Tulman
Department of Pathobiology, University of Connecticut
6 shared publications- Edan R. Tulman
Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, USA
6 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (11)
Immune responses induced by a subunit vaccine against Mycoplasma gallisepticum
Mycoplasma gallisepticum (MG) is an avian respiratory pathogen responsible for global economic loss to the poultry industry. We previously developed an efficacious subunit vaccine to address the drawbacks of current bacterin and live-attenuated vaccine designs. To improve our understanding of how the subunit vaccine works, we sought to understand if the vaccine influences the biology of the pathogen, whether the subunit vaccine has correlates of protection when analyzing antibody responses or tracheal-associated cells, and whether each component of the subunit vaccine contributes to protection. We performed five experiments to answer these questions. In the first experiment, we found that the subunit vaccine induces changes in the in vivo vlhA expression patterns of the infecting MG. We also found that on day 1 post-challenge, anti-VlhA 3.06 systemic IgY correlated negatively with the thickest tracheal mucosal section. In the second experiment, we found that on day 1 post-challenge, anti-MG lysate systemic IgY, anti-VlhA 3.03 systemic IgY, and anti-VlhA 5.05 systemic IgY negatively correlated with bacterial recovery. We also found that when looking at tracheal-associated cell frequencies, γδ T cells, with specific regard to CD8 − γδ T cells, and monocytes/macrophages, with specific regard to the monocyte/macrophage:granulocyte ratio, were negatively correlated with bacterial recovery, average tracheal mucosal thickness, or thickest tracheal mucosal section. In experiments three through five, we found that VlhAs 3.03, 3.06, and 5.05 contributed to reducing bacterial recovery, whereas VlhA 4.07 was dispensable, and we found that GapA and CrmA contributed to reducing bacterial recovery and average tracheal mucosal thickness.
- 10 November 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (11)
Open AccessImmune responses induced by a subunit vaccine against Mycoplasma gallisepticum
Mycoplasma gallisepticum (MG) is an avian respiratory pathogen responsible for global economic loss to the poultry industry. We previously developed an efficacious subunit vaccine to address the drawbacks of current bacterin and live-attenuated vaccine designs. To improve our understanding of how the subunit vaccine works, we sought to understand if the vaccine influences the biology of the pathogen, whether the subunit vaccine has correlates of protection when analyzing antibody responses or tracheal-associated cells, and whether each component of the subunit vaccine contributes to protection. We performed five experiments to answer these questions. In the first experiment, we found that the subunit vaccine induces changes in the in vivo vlhA expression patterns of the infecting MG. We also found that on day 1 post-challenge, anti-VlhA 3.06 systemic IgY correlated negatively with the thickest tracheal mucosal section. In the second experiment, we found that on day 1 post-challenge, anti-MG lysate systemic IgY, anti-VlhA 3.03 systemic IgY, and anti-VlhA 5.05 systemic IgY negatively correlated with bacterial recovery. We also found that when looking at tracheal-associated cell frequencies, γδ T cells, with specific regard to CD8 − γδ T cells, and monocytes/macrophages, with specific regard to the monocyte/macrophage:granulocyte ratio, were negatively correlated with bacterial recovery, average tracheal mucosal thickness, or thickest tracheal mucosal section. In experiments three through five, we found that VlhAs 3.03, 3.06, and 5.05 contributed to reducing bacterial recovery, whereas VlhA 4.07 was dispensable, and we found that GapA and CrmA contributed to reducing bacterial recovery and average tracheal mucosal thickness.
- Open Access
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1844390
Host transcriptional programs underlying lesion development in contagious bovine pleuropneumonia
Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma mycoides subsp. mycoides (Mmm) , remains a major burden to cattle health and the agricultural industry. Mmm is an atypical bacterial pathogen that appears to lack classical virulence factors that cause direct tissue injury (i.e. toxins), and little is known about the mechanisms driving its pathogenicity. The host immune response is believed to be implicated in CBPP pathology, though the molecular mechanisms underlying lesion initiation, progression and chronicity are poorly defined. Classical pathology describes a continuum of lung lesions starting from early inflammation to more mature necrotic lesions and formation of fibrotic sequestra. However, the host transcriptional response driving this potentially immunopathological progression during Mmm infection has never been resolved in vivo . Here, we performed lesion-stage-resolved transcriptomic profiling of pathological lung tissue collected from experimentally infected animals and compared to healthy lung tissue collected from unchallenged controls. Differential gene expression and functional enrichment analyses were used to identify biological pathways relevant to Mmm infection and pathological lesion formation. Early infection was dominated by interferon-stimulated genes and cytokine-responsive pathways, creating a primarily antiviral-like response environment despite the bacterial etiology. Red hepatization showed strong induction of neutrophil chemoattractants, epithelial remodeling markers, and early matrix-remodeling enzymes. Consolidation, spanning red and grey stages, was enriched for innate immune activation, leukocyte adhesion, extracellular matrix organization, and persistent interferon signaling. Grey hepatization reflected late-stage consolidation with heightened neutrophil effector activity, oxidative and proteolytic injury, and macrophage and fibroblast-linked collagen processing. Necrosis/Sequestra lesions showed reduced inflammatory signaling, robust extracellular matrix organization, adhesion, and morphogenetic pathways consistent with encapsulation and sequestrum formation. Our transcriptomic data presented here indicate that the dynamic continuum of CBPP lung pathology appears to be initiated by interferon-primed myeloid recruitment and amplified by neutrophil-driven injury and macrophage- and fibroblast-mediated matrix remodeling, which should be mechanistically investigated. These data further substantiate the role of dysregulated immunity in the development of disease during Mmm infection.
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1844390
Open AccessHost transcriptional programs underlying lesion development in contagious bovine pleuropneumonia
Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma mycoides subsp. mycoides (Mmm) , remains a major burden to cattle health and the agricultural industry. Mmm is an atypical bacterial pathogen that appears to lack classical virulence factors that cause direct tissue injury (i.e. toxins), and little is known about the mechanisms driving its pathogenicity. The host immune response is believed to be implicated in CBPP pathology, though the molecular mechanisms underlying lesion initiation, progression and chronicity are poorly defined. Classical pathology describes a continuum of lung lesions starting from early inflammation to more mature necrotic lesions and formation of fibrotic sequestra. However, the host transcriptional response driving this potentially immunopathological progression during Mmm infection has never been resolved in vivo . Here, we performed lesion-stage-resolved transcriptomic profiling of pathological lung tissue collected from experimentally infected animals and compared to healthy lung tissue collected from unchallenged controls. Differential gene expression and functional enrichment analyses were used to identify biological pathways relevant to Mmm infection and pathological lesion formation. Early infection was dominated by interferon-stimulated genes and cytokine-responsive pathways, creating a primarily antiviral-like response environment despite the bacterial etiology. Red hepatization showed strong induction of neutrophil chemoattractants, epithelial remodeling markers, and early matrix-remodeling enzymes. Consolidation, spanning red and grey stages, was enriched for innate immune activation, leukocyte adhesion, extracellular matrix organization, and persistent interferon signaling. Grey hepatization reflected late-stage consolidation with heightened neutrophil effector activity, oxidative and proteolytic injury, and macrophage and fibroblast-linked collagen processing. Necrosis/Sequestra lesions showed reduced inflammatory signaling, robust extracellular matrix organization, adhesion, and morphogenetic pathways consistent with encapsulation and sequestrum formation. Our transcriptomic data presented here indicate that the dynamic continuum of CBPP lung pathology appears to be initiated by interferon-primed myeloid recruitment and amplified by neutrophil-driven injury and macrophage- and fibroblast-mediated matrix remodeling, which should be mechanistically investigated. These data further substantiate the role of dysregulated immunity in the development of disease during Mmm infection.
- Open Access
- 12 June 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (7) , e0002526
Recombinant subunit vaccine against Mycoplasma gallisepticum disease confers cross-protection against multiple pathogenic strains
Mycoplasma gallisepticum (MG) is an avian respiratory pathogen of global concern, responsible for hundreds of millions of dollars in estimated economic damage each year. Given that MG is distributed across every continent except Antarctica, any globally applicable vaccine must provide protection against numerous strains. We previously published that an R low -based subunit vaccine reduced both MG bacterial burden and tracheal pathology in a homologous infection model using virulent MG strain R low . It remains unknown if the subunit vaccine could reduce disease burden induced by heterologous MG strains. To test this, we utilized a prime-boost schedule and challenged with either strain VA94 or Ap3AS. The vaccine significantly reduced disease burden induced by both heterologous strains as indicated by reduced MG burden and by reduced tracheal pathology. This demonstrates that an MG subunit vaccine has global potential.
- 12 June 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (7) , e0002526
Open AccessRecombinant subunit vaccine against Mycoplasma gallisepticum disease confers cross-protection against multiple pathogenic strains
Mycoplasma gallisepticum (MG) is an avian respiratory pathogen of global concern, responsible for hundreds of millions of dollars in estimated economic damage each year. Given that MG is distributed across every continent except Antarctica, any globally applicable vaccine must provide protection against numerous strains. We previously published that an R low -based subunit vaccine reduced both MG bacterial burden and tracheal pathology in a homologous infection model using virulent MG strain R low . It remains unknown if the subunit vaccine could reduce disease burden induced by heterologous MG strains. To test this, we utilized a prime-boost schedule and challenged with either strain VA94 or Ap3AS. The vaccine significantly reduced disease burden induced by both heterologous strains as indicated by reduced MG burden and by reduced tracheal pathology. This demonstrates that an MG subunit vaccine has global potential.
- Open Access
A 14-Color Blue-Violet Laser Restricted Full Spectrum Flow Cytometry Panel for Comprehensive Immunophenotyping of Pulmonary Inflammation in Mouse Bronchoalveolar Lavage Fluid
Here we describe a 16-parameter, 14-color surface staining panel optimized for murine bronchoalveolar lavage cells that enables reproducible identification of major innate and adaptive immune populations relevant to pulmonary infections or other inflammatory conditions of the airways. The panel enables confident identification of neutrophils, eosinophils, B cells, T cells and subtypes, NK cells, and distinguishes between tissue resident and monocyte-derived macrophages populations. The panel was carefully designed for BAL samples that vary in cell number, are rich in debris, and often autofluorescent. Antibody concentrations are optimized to provide reproducible results regardless of sample-variable cell numbers allowing for the preparation of a single antibody cocktail master mix and rapid sample staining time, thereby cutting down on sample preparation and optimizing cell viability of analyzed samples. The panel facilitates robust cross-sectional and longitudinal comparison of airway inflammation across different airway inflammatory conditions, infections by different respiratory pathogens, impact of vaccination or therapeutics on the inflammatory landscape, and more. It facilitates hypothesis generation by revealing recruitment kinetics and remodeling of myeloid compartments, supports downstream sorting for transcriptomic or functional assays, and provides a standardized baseline for labs to adopt or extend for activation or intracellular cytokine analyses. We have successfully utilized this panel to identify differential host responses to different respiratory Mycoplasma pathogens as well as to longitudinally track the progression of inflammatory response to Mycoplasma pneumoniae over a 21-day time course study. This panel provides an economic immunophenotyping option by utilizing only 14 markers and a two laser (Blue and Violet) full spectrum cytometer to provide comprehensive immunophenotyping power of both myeloid and lymphoid cells. Furthered by lacking the requirement for advanced unmixing for sample analysis, the panel can be easily adopted by the community, enabling comparative meta-analyses of host responses across murine respiratory infection models.
Open AccessA 14-Color Blue-Violet Laser Restricted Full Spectrum Flow Cytometry Panel for Comprehensive Immunophenotyping of Pulmonary Inflammation in Mouse Bronchoalveolar Lavage Fluid
Here we describe a 16-parameter, 14-color surface staining panel optimized for murine bronchoalveolar lavage cells that enables reproducible identification of major innate and adaptive immune populations relevant to pulmonary infections or other inflammatory conditions of the airways. The panel enables confident identification of neutrophils, eosinophils, B cells, T cells and subtypes, NK cells, and distinguishes between tissue resident and monocyte-derived macrophages populations. The panel was carefully designed for BAL samples that vary in cell number, are rich in debris, and often autofluorescent. Antibody concentrations are optimized to provide reproducible results regardless of sample-variable cell numbers allowing for the preparation of a single antibody cocktail master mix and rapid sample staining time, thereby cutting down on sample preparation and optimizing cell viability of analyzed samples. The panel facilitates robust cross-sectional and longitudinal comparison of airway inflammation across different airway inflammatory conditions, infections by different respiratory pathogens, impact of vaccination or therapeutics on the inflammatory landscape, and more. It facilitates hypothesis generation by revealing recruitment kinetics and remodeling of myeloid compartments, supports downstream sorting for transcriptomic or functional assays, and provides a standardized baseline for labs to adopt or extend for activation or intracellular cytokine analyses. We have successfully utilized this panel to identify differential host responses to different respiratory Mycoplasma pathogens as well as to longitudinally track the progression of inflammatory response to Mycoplasma pneumoniae over a 21-day time course study. This panel provides an economic immunophenotyping option by utilizing only 14 markers and a two laser (Blue and Violet) full spectrum cytometer to provide comprehensive immunophenotyping power of both myeloid and lymphoid cells. Furthered by lacking the requirement for advanced unmixing for sample analysis, the panel can be easily adopted by the community, enabling comparative meta-analyses of host responses across murine respiratory infection models.
- Open Access
Paying upfront: successful initial infections protect against severe future infections
Understanding the consistency with which individual hosts respond to repeated pathogen exposures is crucial for accurately modeling pathogen transmission and eco-evolutionary dynamics. When hosts face repeated pathogen exposures, immune memory is expected to reduce the probability and/or severity of subsequent infections, yet it remains unclear whether individuals remain consistent in their level of response relative to others. We investigated this question in house finches ( Haemorhous mexicanus ) from two populations varying in history of endemism of the bacterial pathogen Mycoplasma gallisepticum (MG). Individuals were confirmed to be MG-naive at capture and then experimentally inoculated twice with MG, allowing recovery between inoculations. We then asked if host responses to the second inoculation were predicted by responses to initial inoculation, sex, or population of origin. Our results suggest that individuals were not consistent in their relative response levels; rather, a successful initial infection provided protection against a severe second infection, increasing both tolerance and resistance. While we found no population differences in response to the second inoculation, males showed higher susceptibility to the second inoculation than females. Investigating and accounting for individual variation in response to subsequent exposures may improve the precision and accuracy of transmission models for wildlife pathogens.
Open AccessPaying upfront: successful initial infections protect against severe future infections
Understanding the consistency with which individual hosts respond to repeated pathogen exposures is crucial for accurately modeling pathogen transmission and eco-evolutionary dynamics. When hosts face repeated pathogen exposures, immune memory is expected to reduce the probability and/or severity of subsequent infections, yet it remains unclear whether individuals remain consistent in their level of response relative to others. We investigated this question in house finches ( Haemorhous mexicanus ) from two populations varying in history of endemism of the bacterial pathogen Mycoplasma gallisepticum (MG). Individuals were confirmed to be MG-naive at capture and then experimentally inoculated twice with MG, allowing recovery between inoculations. We then asked if host responses to the second inoculation were predicted by responses to initial inoculation, sex, or population of origin. Our results suggest that individuals were not consistent in their relative response levels; rather, a successful initial infection provided protection against a severe second infection, increasing both tolerance and resistance. While we found no population differences in response to the second inoculation, males showed higher susceptibility to the second inoculation than females. Investigating and accounting for individual variation in response to subsequent exposures may improve the precision and accuracy of transmission models for wildlife pathogens.
- Open Access
Colder temperatures augment viability of an indirectly transmitted songbird pathogen on bird feeders
Inanimate surfaces that are contaminated with infectious pathogens are common sources of spread for many communicable diseases. Understanding how ambient temperature alters the ability of pathogens to remain viable on these surfaces is critical for understanding how fomites can contribute to seasonal patterns of disease outbreaks. House finches (Haemorhous mexicanus) experience fall and winter outbreaks of mycoplasmal conjunctivitis, caused by the bacterial pathogen Mycoplasma gallisepticum (MG). Although bird feeder surfaces serve as an indirect route of MG transmission between sick and healthy individuals, the contributions of feeders to MG transmission in the wild will depend on how ambient temperature affects viability and pathogenicity of MG on feeder surfaces over time. Here, we used two experiments, with identical initial design, to assess such temperature effects. For both experiments, we pipetted equal amounts of MG onto replicate feeder ports held at night‐day temperatures representing summer (22–27°C) or winter (4–9°C). We allowed MG to incubate on feeders at either temperature and swabbed remaining inocula from surfaces at 0, 1, 2, 4, or 7 days post‐inoculation of the feeder, with each replicate feeder port only swabbed at a single time point. In the first study, we analyzed swabs using a culture‐based assay and found that MG incubated at colder versus warmer temperatures maintained higher viability on feeder surfaces over time. In the second study, we replicated the same experimental design but used MG swabs from feeder surfaces to inoculate wild‐caught, pathogen‐naïve birds and measured resulting disease severity and pathogen loads to determine pathogenicity. We found that MG remained pathogenic on feeder surfaces at cold ambient temperatures for up to one week, much longer than previously documented. Further, MG was significantly more pathogenic when incubated on feeders in colder versus warmer temperatures, with the strongest effects of temperature present after at least four days of incubation on feeder surfaces. Overall, cold ambient temperatures appear to alter the role of fomites in the MG transmission process, and temperature likely contributes to seasonal disease dynamics in this system and many others.
Open AccessColder temperatures augment viability of an indirectly transmitted songbird pathogen on bird feeders
Inanimate surfaces that are contaminated with infectious pathogens are common sources of spread for many communicable diseases. Understanding how ambient temperature alters the ability of pathogens to remain viable on these surfaces is critical for understanding how fomites can contribute to seasonal patterns of disease outbreaks. House finches (Haemorhous mexicanus) experience fall and winter outbreaks of mycoplasmal conjunctivitis, caused by the bacterial pathogen Mycoplasma gallisepticum (MG). Although bird feeder surfaces serve as an indirect route of MG transmission between sick and healthy individuals, the contributions of feeders to MG transmission in the wild will depend on how ambient temperature affects viability and pathogenicity of MG on feeder surfaces over time. Here, we used two experiments, with identical initial design, to assess such temperature effects. For both experiments, we pipetted equal amounts of MG onto replicate feeder ports held at night‐day temperatures representing summer (22–27°C) or winter (4–9°C). We allowed MG to incubate on feeders at either temperature and swabbed remaining inocula from surfaces at 0, 1, 2, 4, or 7 days post‐inoculation of the feeder, with each replicate feeder port only swabbed at a single time point. In the first study, we analyzed swabs using a culture‐based assay and found that MG incubated at colder versus warmer temperatures maintained higher viability on feeder surfaces over time. In the second study, we replicated the same experimental design but used MG swabs from feeder surfaces to inoculate wild‐caught, pathogen‐naïve birds and measured resulting disease severity and pathogen loads to determine pathogenicity. We found that MG remained pathogenic on feeder surfaces at cold ambient temperatures for up to one week, much longer than previously documented. Further, MG was significantly more pathogenic when incubated on feeders in colder versus warmer temperatures, with the strongest effects of temperature present after at least four days of incubation on feeder surfaces. Overall, cold ambient temperatures appear to alter the role of fomites in the MG transmission process, and temperature likely contributes to seasonal disease dynamics in this system and many others.
- Open Access
- 28 September 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-12
Rationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach
Mycoplasma gallisepticum (MG) is an avian respiratory pathogen causing significant global economic losses to the poultry industries. Current live-attenuated and bacterin vaccines provide some measures of protective immunity but exhibit suboptimal efficacy, utility, or safety. To address these shortcomings, we utilized knowledge of MG biology and virulence to develop a subunit vaccine containing recombinantly produced primary adhesin GapA, cytadhesin-related molecule CrmA, and four early-phase-expressed variable lipoprotein hemagglutinins (VlhAs) (3.03, 3.06, 4.07, 5.05) of the virulent strain Rlow. The vaccine was tested in chickens using a subcutaneous dose of 50 µg per protein, a prime-boost schedule, and strain Rlow challenge in multiple studies to compare adjuvant formulations. While different adjuvants resulted in variable levels of protection, only CpG oligodeoxynucleotide (CpG ODN 2007) resulted in significant reductions of both MG recovery and tracheal pathology. These results demonstrate that a rationally designed and safe subunit vaccine is efficacious against MG disease.
- 28 September 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-12
Open AccessRationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach
Mycoplasma gallisepticum (MG) is an avian respiratory pathogen causing significant global economic losses to the poultry industries. Current live-attenuated and bacterin vaccines provide some measures of protective immunity but exhibit suboptimal efficacy, utility, or safety. To address these shortcomings, we utilized knowledge of MG biology and virulence to develop a subunit vaccine containing recombinantly produced primary adhesin GapA, cytadhesin-related molecule CrmA, and four early-phase-expressed variable lipoprotein hemagglutinins (VlhAs) (3.03, 3.06, 4.07, 5.05) of the virulent strain Rlow. The vaccine was tested in chickens using a subcutaneous dose of 50 µg per protein, a prime-boost schedule, and strain Rlow challenge in multiple studies to compare adjuvant formulations. While different adjuvants resulted in variable levels of protection, only CpG oligodeoxynucleotide (CpG ODN 2007) resulted in significant reductions of both MG recovery and tracheal pathology. These results demonstrate that a rationally designed and safe subunit vaccine is efficacious against MG disease.
- Open Access
- 31 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-13
B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs
Development of an effective vaccine for Mycoplasma pneumoniae has been hindered by reports of Vaccine Enhanced Disease (VED) in test subjects vaccinated and challenged in studies conducted in the 1960s. The exact mechanism of disease exacerbation has yet to be fully described, but host immune responses to Lipid-Associated Membrane Proteins (LAMPs) lipoprotein lipid moieties have been implicated. LAMPs-induced exacerbation appears to involve helper T cell recall responses, due in part to their influence on neutrophil recruitment and subsequent inflammatory responses in the lung. Herein, we characterized the functions of host B cell responses to M. pneumoniae LAMPs and delipidated-LAMPs (dLAMPs) by conducting passive transfer and B cell depletion studies to assess their contribution to disease exacerbation or protection using a BALB/c mouse model. We found that antibody responses to M. pneumoniae LAMPs and dLAMPs differ in magnitude, but not in isotype or subclass. Passive transfer, dLAMP denaturation, and monoclonal antibody studies indicate that antibodies do not cause VED, but do appear to contribute to control of bacterial loads in the lungs. Depletion of B cells prior to LAMPs-vaccination results in significantly enhanced pathology in comparison to B cell competent controls, suggesting a possible regulatory role of B cells distinct from antibody secretion. Taken together, our findings suggest that B cell antibody responses to M. pneumoniae contribute to, but are insufficient for protection against challenge on their own, and that other functional properties of B cells are necessary to limit exacerbation of disease in LAMPs-vaccinated mice after infection.
- 31 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-13
Open AccessB cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs
Development of an effective vaccine for Mycoplasma pneumoniae has been hindered by reports of Vaccine Enhanced Disease (VED) in test subjects vaccinated and challenged in studies conducted in the 1960s. The exact mechanism of disease exacerbation has yet to be fully described, but host immune responses to Lipid-Associated Membrane Proteins (LAMPs) lipoprotein lipid moieties have been implicated. LAMPs-induced exacerbation appears to involve helper T cell recall responses, due in part to their influence on neutrophil recruitment and subsequent inflammatory responses in the lung. Herein, we characterized the functions of host B cell responses to M. pneumoniae LAMPs and delipidated-LAMPs (dLAMPs) by conducting passive transfer and B cell depletion studies to assess their contribution to disease exacerbation or protection using a BALB/c mouse model. We found that antibody responses to M. pneumoniae LAMPs and dLAMPs differ in magnitude, but not in isotype or subclass. Passive transfer, dLAMP denaturation, and monoclonal antibody studies indicate that antibodies do not cause VED, but do appear to contribute to control of bacterial loads in the lungs. Depletion of B cells prior to LAMPs-vaccination results in significantly enhanced pathology in comparison to B cell competent controls, suggesting a possible regulatory role of B cells distinct from antibody secretion. Taken together, our findings suggest that B cell antibody responses to M. pneumoniae contribute to, but are insufficient for protection against challenge on their own, and that other functional properties of B cells are necessary to limit exacerbation of disease in LAMPs-vaccinated mice after infection.
- Open Access
- 29 July 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-14
Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease
Bacterial lipoproteins are an often-underappreciated class of microbe-associated molecular patterns with potent immunomodulatory activity. We previously reported that vaccination of BALB/c mice withMycoplasma pneumoniae(Mp) lipid-associated membrane proteins (LAMPs) resulted in lipoprotein-dependent vaccine enhanced disease after challenge with virulentMp, though the immune responses underpinning this phenomenon remain poorly understood. Herein, we report that lipoprotein-induced VED in a mouse model is associated with elevated inflammatory cytokines TNF-α, IL-1β, IL-6, IL-17A, and KC in lung lavage fluid and with suppurative pneumonia marked by exuberant neutrophilia in the pulmonary parenchyma. Whole-lung-digest flow cytometry and RNAScope analysis identified multiple cellular sources for IL-17A, and the numbers of IL-17A producing cells were increased in LAMPs-vaccinated/Mp-challenged animals compared to controls. Specific IL-17A or neutrophil depletion reduced disease severity in our VED model—indicating thatMplipoproteins induce VED in an IL-17A-dependent manner and through exuberant neutrophil recruitment. IL-17A neutralization reduced levels of TNF-α, IL-1β, IL-6, and KC, indicating that IL-17A preceded other inflammatory cytokines. Surprisingly, we found that IL-17A neutralization impaired bacterial clearance, while neutrophil depletion improved it—indicating that, while IL-17A appears to confer both maladaptive and protective responses, neutrophils play an entirely maladaptive role in VED. Given that lipoproteins are found in virtually all bacteria, the potential for lipoprotein-mediated maladaptive inflammatory responses should be taken into consideration when developing vaccines against bacterial pathogens.
- 29 July 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-14
Open AccessVaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease
Bacterial lipoproteins are an often-underappreciated class of microbe-associated molecular patterns with potent immunomodulatory activity. We previously reported that vaccination of BALB/c mice withMycoplasma pneumoniae(Mp) lipid-associated membrane proteins (LAMPs) resulted in lipoprotein-dependent vaccine enhanced disease after challenge with virulentMp, though the immune responses underpinning this phenomenon remain poorly understood. Herein, we report that lipoprotein-induced VED in a mouse model is associated with elevated inflammatory cytokines TNF-α, IL-1β, IL-6, IL-17A, and KC in lung lavage fluid and with suppurative pneumonia marked by exuberant neutrophilia in the pulmonary parenchyma. Whole-lung-digest flow cytometry and RNAScope analysis identified multiple cellular sources for IL-17A, and the numbers of IL-17A producing cells were increased in LAMPs-vaccinated/Mp-challenged animals compared to controls. Specific IL-17A or neutrophil depletion reduced disease severity in our VED model—indicating thatMplipoproteins induce VED in an IL-17A-dependent manner and through exuberant neutrophil recruitment. IL-17A neutralization reduced levels of TNF-α, IL-1β, IL-6, and KC, indicating that IL-17A preceded other inflammatory cytokines. Surprisingly, we found that IL-17A neutralization impaired bacterial clearance, while neutrophil depletion improved it—indicating that, while IL-17A appears to confer both maladaptive and protective responses, neutrophils play an entirely maladaptive role in VED. Given that lipoproteins are found in virtually all bacteria, the potential for lipoprotein-mediated maladaptive inflammatory responses should be taken into consideration when developing vaccines against bacterial pathogens.
- 1 December 2020
- Published by Elsevier in Veterinary Microbiology
- Vol. 251, 108891
The influence of host tissue on M. gallisepticum vlhA gene expression
- 1 December 2020
- Published by Elsevier in Veterinary Microbiology
- Vol. 251, 108891
The influence of host tissue on M. gallisepticum vlhA gene expression